Role of Serum Cystatin C in Assessing Kidney Function

Advantages of Cystatin C as a Kidney Function Marker

Cystatin C is a protein from the cystatin superfamily of cysteine proteinase inhibitors expressed in all nucleated cells, produced at a constant rate, not secreted, and catabolized in the tubules without returning to bloodstream, making it a valuable marker for kidney function assessment 1
The American Society of Nephrology suggests that cystatin C is independent of age, sex, and muscle mass, making it particularly valuable in populations where creatinine may be unreliable 1
Cystatin C may detect kidney dysfunction at an earlier stage than creatinine in people with diabetes, according to the American Diabetes Association 2

Clinical Applications and Recommendations

The National Kidney Foundation recommends using cystatin C for confirmatory testing in specific circumstances when eGFR based on serum creatinine is less accurate, such as in individuals with low muscle mass 2
The American Journal of Kidney Diseases suggests measuring cystatin C in adults with eGFRcreat 45–59 mL/min/1.73m² who do not have markers of kidney damage if confirmation of CKD is required 3
If eGFRcys/eGFRcreat-cys is ≥60 mL/min/1.73m², the diagnosis of CKD is not confirmed, as recommended by the American Journal of Kidney Diseases 3

Reporting and Interpretation

Clinical laboratories should measure serum cystatin C using an assay with calibration traceable to the international standard reference material, as recommended by the American Journal of Kidney Diseases 3
Cystatin C concentration should be reported rounded to the nearest 100th of a whole number when expressed as conventional units (mg/L), according to the American Journal of Kidney Diseases 3

Limitations and Considerations

Despite its advantages, cystatin C assays are not widely available in many countries, including the U.S. and Canada, as noted by the American Journal of Kidney Diseases and Diabetes Care 2, 4
The biggest issue is lack of evidence of effectiveness and cost-effectiveness, as reported by the American Journal of Kidney Diseases 4

Combined Use with Other Markers

The National Kidney Foundation and American Society of Nephrology recommend combining filtration markers (creatinine and cystatin C) as this is more accurate and would support better clinical decisions than either marker alone 2
A model incorporating both cystatin C and serum creatinine into the formula—along with variables related to muscle mass—was found superior to those utilizing either marker alone to predict clearance of carboplatin in cancer patients, as reported by the Annals of Oncology 1

Future Directions

The 2021 CKD-EPI creatinine equation refit without the race variable is recommended for immediate implementation in all laboratories in the United States, as suggested by Diabetes Care 2
National efforts to facilitate increased, routine, and timely use of cystatin C are recommended, especially to confirm eGFR in adults who are at risk for or have CKD, according to Diabetes Care 2

Cystatin C as a Biomarker for Kidney Function Assessment

Clinical Applications

The Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest measuring cystatin C in adults with estimated GFR based on creatinine (eGFRcreat) of 45–59 mL/min/1.73 m² who do not have markers of kidney damage 5
Cystatin C can be used to estimate GFR in children with chronic liver disease, as recommended by the revised Schwartz Formula 6
In cancer patients, cystatin C may improve dose individualization of cytotoxic drugs to achieve target AUC and reduce toxicity, according to the American College of Oncology 7
The American Association for the Study of Liver Diseases recommends using cystatin C-based equations to estimate measured GFR in liver transplant recipients 8

Estimation Equations Using Cystatin C

The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend using three main equations, including cystatin C alone (eGFRcys), creatinine alone (eGFRcreat), and a combined equation using both markers (eGFRcreat-cys) 5, 9

Limitations and Considerations

Thyroid dysfunction can affect cystatin C levels independently of renal function, as noted in the Hepatology journal 6

Evaluación de la Función Renal con Creatinina y Cistatina C

Introducción a los Marcadores Renales

La combinación de creatinina y cistatina C proporciona la evaluación más precisa de la función renal, siendo superior a cualquiera de estos marcadores por separado para estimar la tasa de filtración glomerular (TFG) 10, 11

Significado Clínico de los Marcadores Renales

La creatinina sérica es un producto del metabolismo muscular que se filtra libremente por el glomérulo, pero presenta limitaciones importantes como marcador único de función renal 11
Los niveles de creatinina pueden verse afectados por factores no relacionados con la TFG como masa muscular, edad, sexo y dieta 10, 12
La creatinina es menos precisa en poblaciones específicas como niños, ancianos, pacientes con baja masa muscular o enfermedades crónicas 13, 11

Uso de Cistatina C

La cistatina C es más sensible para detectar deterioros leves de la función renal y no se ve afectada significativamente por la masa muscular, edad o sexo 10
La cistatina C es especialmente útil en pacientes con alteraciones de la masa muscular, deportistas, obesidad clase III, enfermedad hepática crónica y en la evaluación de la función renal en niños con enfermedad hepática 10, 14, 13

Ecuaciones para Estimar la TFG

La ecuación eGFRcr-cys, que combina creatinina y cistatina C, es más precisa para estimar la TFG 10, 11
La American Journal of Kidney Diseases recomienda utilizar la ecuación basada en creatinina (eGFRcr) en adultos con riesgo de enfermedad renal crónica, y si la cistatina C está disponible, estimar la TFG mediante la combinación de creatinina y cistatina C (eGFRcr-cys) para mayor precisión 15, 10

Consideraciones Especiales y Limitaciones

La creatinina tiene baja sensibilidad para detectar cambios tempranos en la función renal y requiere estabilidad en la función renal para ser interpretada correctamente 12
La cistatina C puede verse afectada por disfunción tiroidea, tabaquismo y algunos tipos de cáncer, y requiere métodos de ensayo estandarizados y calibrados 10, 11

Aplicación Clínica

La evaluación integral de la función renal debe incluir la medición de creatinina, cistatina C y albúmina urinaria para detectar enfermedad renal crónica (ERC) 10, 15
La cistatina C puede ser útil para la estratificación de riesgo y pronóstico en pacientes con insuficiencia cardíaca 12

Cystatin C in Kidney Function Assessment

Key Findings

The KDIGO guidelines recommend measuring cystatin C in adults with eGFRcreat 45–59 mL/min/1.73m² who do not have markers of kidney damage if confirmation of CKD is required 16
Combining filtration markers (creatinine and cystatin C) provides more accurate GFR estimation and better clinical decisions than either marker alone 16, 17
In a meta-analysis of 90,750 participants across 16 cohort studies, 23% of persons with eGFRcreat 60–74 ml/min/1.73 m² had eGFRcys <60 ml/min/1.73 m², indicating potential underdiagnosis of CKD when using creatinine alone 18
Cystatin C markedly strengthens the association between eGFR and cardiovascular events, kidney failure, and death 19
The National Kidney Foundation and American Society of Nephrology recommend national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults who are at risk for or have CKD 17
Cystatin C may not be required for routine monitoring after the diagnosis of CKD is made 19
Despite its advantages, cystatin C assays are not widely available in many countries, including the U.S. 17
The cost of testing is higher than creatinine, though the "triple marker" panel of serum creatinine, serum cystatin C, and urine albumin-to-creatinine ratio is considered affordable in high-income settings 18, 19

Clinical Applications

The American College of Cardiology recommends using cystatin C to assess kidney function in patients with cardiovascular disease 16
Cystatin C can detect kidney dysfunction at an earlier stage than creatinine in people with diabetes and other conditions 17

Risk Stratification

Elevated cystatin C levels are associated with increased risk of major cardiovascular events, development of chronic kidney disease, and cardiovascular and all-cause mortality 19

Indications for Cystatin C in Renal Function Work-Up

Primary Indications Based on Body Habitus and Muscle Mass Alterations

The KDIGO guidelines recommend using cystatin C when serum creatinine-based eGFR estimates are unreliable due to altered muscle mass, in patients with eGFR 45-59 mL/min/1.73m² requiring CKD confirmation, and when accurate GFR assessment is critical for treatment decisions involving nephrotoxic drugs or dose adjustments 20, 21
For patients with eating disorders, the KDIGO guidelines suggest using eGFRcys when no comorbid illness exists beyond muscle mass reduction 20, 21
For patients with above-knee amputation, eGFRcys is appropriate without comorbidities, while eGFRcr-cys is recommended if comorbid illness is present 20, 21
For patients with spinal cord injury, eGFRcys is recommended for patients without comorbidities, while eGFRcr-cys is suggested with comorbid conditions 20, 21
For patients with neuromuscular diseases, creatinine-based equations may overestimate GFR, but cystatin C shows lower bias 20, 21
For extreme athletes or bodybuilders, eGFRcys is appropriate when increased muscle mass is the only abnormality 20, 21
For patients with class III obesity, combined eGFRcr-cys is demonstrated to be most accurate, as both creatinine and cystatin C have non-GFR determinants in this population 20, 21

Confirmatory Testing for CKD Diagnosis

The KDIGO guidelines recommend measuring cystatin C in adults with eGFRcreat 45-59 mL/min/1.73m² who lack other markers of kidney damage when CKD confirmation is required 20, 21

Chronic Illness Requiring Accurate GFR Assessment

For cancer patients, combined eGFRcr-cys is most accurate, though accuracy decreases in frail patients or high cell turnover cancers 20, 21
For cancer patients, cystatin C is superior for predicting carboplatin and topotecan clearance, improving dose individualization and reducing toxicity risk 22
For heart failure patients, eGFRcys shows less bias, though all equations have low accuracy 20, 21
For heart failure patients, eGFRcr-cys or eGFRcys should be used for routine evaluation, and measured GFR (mGFR) should be considered for treatment decisions 20, 21
For patients with cirrhosis, eGFRcys is less biased but accuracy remains limited 20, 21
For patients with cirrhosis, eGFRcr-cys or eGFRcys should be used routinely, and mGFR is recommended for treatment decisions 20, 21
For patients with malnutrition, both creatinine and cystatin C are affected by chronic illness and inflammation 20, 21
For patients with malnutrition, eGFRcr-cys may be less accurate, and mGFR should be strongly considered for treatment decisions 20, 21

Dietary and Lifestyle Factors

For patients on low-protein diets, creatinine production is reduced, making cystatin C a preferred marker 20, 21
For patients on ketogenic diets, limited data suggests that creatinine is affected, making cystatin C a potentially better choice 20, 21
For patients on vegetarian diets, creatinine production is altered, making cystatin C a preferred marker 20, 21
For active smokers, cystatin C has non-GFR determinants, and eGFRcr may be preferred if no changes to creatinine determinants are present 20, 21
For patients on high-protein diets or taking creatine supplements, creatinine is elevated independent of GFR, making cystatin C a potentially better choice 20, 21

Special Populations

For liver transplant recipients, cystatin C-based equations are recommended for estimating GFR 23, 24, 25
For elderly patients, cystatin C is independent of age, making it a more reliable marker than creatinine-based equations 22

Optimal Testing Strategy

The combined creatinine-cystatin C equation (eGFRcr-cys) provides the most accurate GFR estimation and should be used when both markers are available 20, 21
The 2012 CKD-EPI combined equation should be used for maximum accuracy 23, 24, 25

Estimating Glomerular Filtration Rate with Cystatin C and Creatinine

Introduction to GFR Estimation

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using the combined creatinine-cystatin C equation (eGFRcr-cys) for the most accurate GFR estimation when cystatin C is available 26

Primary Recommendation: Use Combined Equations

The KDIGO guidelines establish that combining both filtration markers yields superior accuracy compared to either marker alone, with the combined equation achieving 89% of estimates within 30% of measured GFR 26

Strategic Use of Cystatin C

The KDIGO guidelines recommend a stepwise approach, starting with creatinine-based eGFR (eGFRcr) for initial assessment in all patients, and measuring cystatin C as a confirmatory test only in specific circumstances when eGFRcr is likely inaccurate 26
The primary indication for cystatin C measurement is adults with eGFRcr 45-59 mL/min/1.73 m² who lack other markers of kidney damage 26

Why Cystatin C Alone Is Not Superior

A critical study demonstrated that cystatin C-based strategies provided no added value for CKD detection compared to creatinine alone, with similar misclassification rates (21% vs 23%) 27
Cystatin C can be influenced by factors unrelated to kidney function, such as obesity, inflammation, and metabolic factors, potentially leading to misleading results 27

Specific Clinical Scenarios Where Cystatin C Adds Value

Cystatin C measurement is justified when creatinine-based estimates are unreliable due to altered muscle mass, such as in extremes of muscle mass, extreme athletes or bodybuilders, class III obesity, and dietary extremes 26

Important Limitations and Caveats

The Canadian Society of Nephrology explicitly does not recommend widespread cystatin C use, citing lack of evidence for improved outcomes and cost-effectiveness 28
The biggest barrier to cystatin C use is not just cost, but the absence of data showing that more accurate GFR estimation actually improves patient outcomes 28

Practical Implementation Algorithm

Initial assessment should use eGFRcr for all patients, and consider cystatin C measurement if eGFRcr is 45-59 mL/min/1.73 m² and no albuminuria or other kidney damage markers are present, or if extreme alterations in muscle mass make creatinine unreliable 26
When cystatin C is measured, always calculate eGFRcr-cys (combined equation) 26
Do not use cystatin C for routine CKD monitoring after diagnosis is established, when cost or availability is limited, or in populations where outcomes data are lacking 28